The estimated Net Worth of Diane G. Gerst is at least $1.93 Milione dollars as of 18 July 2022. Ms. Gerst owns over 1,520 units of Amphastar Pharmaceuticals Inc stock worth over $647,295 and over the last 10 years she sold AMPH stock worth over $725,176. In addition, she makes $556,654 as Director at Amphastar Pharmaceuticals Inc.
Diane has made over 20 trades of the Amphastar Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently she exercised 1,520 units of AMPH stock worth $30,522 on 18 July 2022.
The largest trade she's ever made was exercising 24,046 units of Amphastar Pharmaceuticals Inc stock on 19 August 2016 worth over $296,006. On average, Diane trades about 2,624 units every 66 days since 2015. As of 18 July 2022 she still owns at least 14,362 units of Amphastar Pharmaceuticals Inc stock.
You can see the complete history of Ms. Gerst stock trades at the bottom of the page.
Diane G. Gerst serves as Director of the Company. She previously served as our Executive Vice President of Quality Assurance and Regulatory Affairs from June 2015 until February 2018 and also served as the President of Amphastar Nanjing Pharmaceuticals Inc., one of our subsidiaries, from March 2014 until February 2018. From August 2013 to June 2015, Ms. Gerst served as our Corporate Senior Vice President of Quality Assurance. She served as Corporate Vice President of Quality Assurance from August 2003 until her promotion to Senior Vice President in August 2013 and as Vice President of Regulatory Affairs from June 2001 to July 2002. Prior to joining us, Ms. Gerst held various management level positions in regulatory and quality including eight years at Braun-McGaw and seven years at IMS. Ms. Gerst received a B.A. from the University of California, Berkeley.
As the Director of Amphastar Pharmaceuticals Inc, the total compensation of Diane Gerst at Amphastar Pharmaceuticals Inc is $556,654. There are 9 executives at Amphastar Pharmaceuticals Inc getting paid more, with Jack Zhang having the highest compensation of $5,969,740.
Diane Gerst is 60, she's been the Director of Amphastar Pharmaceuticals Inc since 2019. There are 10 older and 5 younger executives at Amphastar Pharmaceuticals Inc. The oldest executive at Amphastar Pharmaceuticals Inc is Richard Koo, 79, who is the Independent Director.
Diane's mailing address filed with the SEC is C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA, CA, 91730.
Over the last 10 years, insiders at Amphastar Pharmaceuticals Inc have traded over $72,457,295 worth of Amphastar Pharmaceuticals Inc stock and bought 66,100 units worth $921,987 . The most active insiders traders include Jack Y.Luo Mary Z. Zhang, Richard K Prins e William J Peters. On average, Amphastar Pharmaceuticals Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,459,051. The most recent stock trade was executed by Floyd F. Petersen on 5 September 2024, trading 3,000 units of AMPH stock currently worth $139,410.
amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int
Amphastar Pharmaceuticals Inc executives and other stock owners filed with the SEC include: